Heart Failure Society of America

The Heart Failure Society of America annual scientific meeting features the latest in management and late-breaking clinical data related to heart failure.

HFSA 2021: The Physician Assistant Experience, With Viet Le, PA-C

September 22, 2021

Viet Le, PA-C, details his experience at the Heart Failure Society of America annual meeting from the perspective of a physician assistant.

Digital Apps Could Improve Outcomes, Adherence Among Patients With Heart Failure

September 17, 2021

Data from the CONNECT-HF trial from HFSA 2021 suggest use of a digital tool designed to improve adherence could contribute to improving outcomes among patients discharged from the hospital with heart failure with reduced ejection fraction.

Aficamten Shows Potential for Hypertrophic Cardiomyopathy in REDWOOD-HCM

September 15, 2021

Presented at HFSA 2021, results of REDWOOD-HCM provide insight into the effects of the oral selective cardiac myosin inhibitor aficamten in patients with obstructive hypertrophic cardiomyopathy.

PRESERVED-HF: Dapagliflozin Reduces Symptom Burden, Physical Limitations in HFpEF

September 14, 2021

Presented at HFSA 2021, PRESERVED-HF provides evidence suggesting dapagliflozin use was associated with improvements in KCCQ symptom score and 6-minute walking distance in patients with heart failure with preserved ejection fraction.